PUBLIC PERCEPTIONS OF PATHOGEN REDUCTION TECHNOLOGY IN THE CANADIAN DONOR BLOOD SUPPLY
2
INDEPENDENT EVALUATION OF TOLERANCE OF THEREAPEUTIC PLASMA INACTIVATED BY AMOTOSALEN-HCI-UVA (INTERCEPT tm) OVER A 5-YEAR PERIOD OF EXTENSIVE DELIVERY
3
EXPANDING ACCESS TO TRANSFUSSION MEDICINE AND IMPROVING PRACTICE: GUIDELINES, PATIENTS BLOOD MANAGEMENT, PROTOCOLS AND PRODUCTS
4
INTERNATIONAL PROSPECTIVE HAEMOVIGILANCE STUDY ON METHYLENE BLUE-TREATED PLASMA
5
MIRASOL PATHOGEN REDUCTION TECHNOLOGY TREATMENT OF HUMAN WHOLE BLOOD DOES NOT INDUCE ACUTE LUNG INJURY IN MICE
6
PATIENT OUTCOMES AND AMOTOSALEN/UVA-TREATED PLATELET UTILIZATION IN MASSIVELY TRANSFUSED PATIENTS
7
RED BLOOD CELL CONCENTRATES TREATED WITH THE AMUSTALINE (S-303) PATHOGEN REDUCTION SYSTEM AND STORED FOR 35 DAYS RETAIN POST-TRANSFUSION VIABILITY: RESULTS OF A TWO-CENTRE STUDY
8
JAPANESE ENCEPHALITIS VIRUS TRANSMITTED VIA BLOOD TRANSFUSION, HONG KONG, CHINA